Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market

Zacks
Öffnen unter Zacks
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market

CRISPR Therapeutics AG (CRSP) closed at $51.36 in the latest trading session, marking a -5.34% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 1.82% for the day. At the same time, the Dow lost 1.09%, and the tech-heavy Nasdaq lost 2.86%.

Prior to today's trading, shares of the company had lost 2.13% lagged the Medical sector's gain of 5.28% and the S&P 500's gain of 0.71%.

Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.06 per share, which would represent year-over-year growth of 9.4%. Simultaneously, our latest consensus estimate expects the revenue to be $9.95 million, showing a 1017.42% escalation compared to the year-ago quarter.

For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.44 per share and revenue of $32.45 million, which would represent changes of +31.38% and +824.53%, respectively, from the prior year.

Investors should also pay attention to any latest changes in analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.59% higher. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 103, positioning it in the top 42% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research